跳至主要内容
临床试验/NCT00871962
NCT00871962Unknown不适用

Long-term Oxygen Treatment (LTOT) in Chronic Obstructive Pulmonary Disease: Factors Influencing Survival: Survival Factors in COPD Treated by Long-term Oxygen Therapy

Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche1 个研究点 分布在 1 个国家目标入组 750 人开始时间: 2009年6月最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
750
试验地点
1
主要终点
Survival in function of initial hypoxemia, body mass index and cardiovascular events

研究概览

简要总结

The purpose of this prospective cohort study is to determine factors involved in survival in new COPD patients treated by long-term oxygen therapy.

Background: long-term oxygen therapy is indicated in patients with severe COPD. No studies have been performed in the past 20-25 years to examine the results of early clinical trials. Further studies are necessary to understand the utility of oxygen therapy in severe COPD.

详细描述

long-term oxygen therapy prolongs life in patients with severe COPD and severe resting hypoxemia. The objective of this study is to measure the survival in relation to the level of initial resting hypoxemia, serious co-morbidities, and nutritional status in COPD patients treated by long-term oxygen therapy. After enrollment at the beginning of oxygen therapy, following data will be collected during 3 years. Lung function, blood gas analysis, exercise capacity measured by the 6-Min Walk Distance test (6-MWD), dyspnea scale, BODE index, quality of life, indirect and direct costs will be analyzed every year.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
40 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • COPD patients on necessity of long-term oxygen therapy
  • Patients treated by LTOT, with or without clinically fulfilled criteria for LTOT, with PaO2<55mmHg or less at rest or during sleeping or less during exercise, if supplemental oxygen is demonstrated to improve the exercise-associated hypoxia. Patients with PaO2 56-59mmHg if they also have dependent edema, pulmonary hypertension or hematocrit higher than 56%
  • Patient clinically stable
  • Patient with oxygen device of ANTADIR network
  • Oral and written consent

排除标准

  • Patient with obstructive sleep apnea or overlap syndrome
  • Patient with non invasive ventilation
  • Patient with evolutive cancer.
  • Inability to complete questionnaires
  • Inability to attend outpatient clinic

结局指标

主要结局

Survival in function of initial hypoxemia, body mass index and cardiovascular events

时间窗: 3 years

次要结局

  • Long-term oxygen therapy observance and duration(3 years)

研究者

发起方
Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验